Compare RBBN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | ALT |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 421.5M |
| IPO Year | 2017 | 2005 |
| Metric | RBBN | ALT |
|---|---|---|
| Price | $2.45 | $3.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.67 | ★ $17.67 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $1.83 | $2.56 |
| 52 Week High | $4.29 | $7.73 |
| Indicator | RBBN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 59.65 |
| Support Level | $2.36 | $2.87 |
| Resistance Level | $2.46 | $3.20 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 2.84 | 94.73 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.